The Risk of Tuberculosis Infection in Non-dialysis Chronic Kidney Disease Patients

Chia-Hsiang Li1,2,3, Hung-Jen Chen2,3, Wei-Chun Chen2,3, Chih-Yen Tu2,3, Te-Chun Hsia2,4, Wu-Huei Hsu2,3, Chiz-Tzung Chang2,6, Chiu-Ching Huang2,5, Da-Tian Bau2,6,7* and Che-Yi Chou5,8,9*

1 Graduate Institute of Biomedical Science, China Medical University, Taichung, Taiwan, 2 School of Medicine, China Medical University, Taichung, Taiwan, 3 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, 4 School of Nursing, China Medical University, Taichung, Taiwan, 5 Division of Nephrology and Kidney, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, 6 Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, 7 Department of Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan, 8 Division of Nephrology, Asia University Hospital, Taichung, Taiwan, 9 Department of Post-baccalaureate Veterinary Medicine, Asia University, Taichung, Taiwan

Background: Patients with chronic kidney disease (CKD) receiving maintenance renal replacement therapy are at higher risk of tuberculosis (TB) infection. The risk of TB infection in CKD patients not receiving dialysis is unknown.

Aim: We conduct this study to test the hypothesis that TB infection is negatively correlated to renal function.

Design: Non-dialysis CKD stage 1–5 patients, admitted in China Medical University Hospital from January of 2003 to May of 2014, were enrolled in this study and were prospectively followed up to the diagnosis of TB, death, loss to follow-up, or December 2014. The risk factors of TB infection were analyzed using competing-risks regression analysis with time-varying covariates. The initiation of dialysis and patients’ death were considered as competing events. Patients’ estimated glomerular filtration rate (eGFR) and body mass index (BMI) were recorded at enrollment.

Results: They were followed-up for a median duration of 1.4 years. Of the 7221 patients, TB infection was identified in 114 patients. Higher eGFR was associated with lower risk of TB infection (P < 0.01). The adjusted subdistribution hazard ratio (aSHR) was 0.82 [95% confidence interval (CI), 0.72 to 0.94] for every 5 ml/min/1.73 m² increase in eGFR. In addition, higher BMI (p = 0.01) was associated with a lower risk of TB infection and the aSHR was 0.91 (95% CI, 0.85 to 0.98) for every 1 kg/m² increase in BMI.

Conclusion: Renal function and body mass index are independently associated with the risk of tuberculosis infection in patients with chronic kidney disease not receiving dialysis.

Keywords: tuberculosis, chronic kidney disease, body mass index, estimate GFR, non-dialysis CKD
INTRODUCTION

Tuberculosis (TB) is a communicable disease caused by bacillus Mycobacterium tuberculosis, typically affecting the lungs. Despite improvements in the public health structure and system, TB remains a serious public health problem worldwide. The risk of TB is high among immunocompromised individuals, especially in patients with human immunodeficiency virus (HIV) infection. The mortality rate of TB infection is higher if left untreated. In a systemic review of patients with pulmonary TB, the 10-year mortality rate was 70% (1). According to the global tuberculosis report 2015, the estimated global incidence of the TB was 10.0 million, and TB is responsible for 1.3 million deaths among HIV-negative people in 2017 (2). There were 12,338 TB cases and 626 TB-related deaths in Taiwan in 2012 (3).

Chronic kidney disease (CKD) is associated with an increased risk of all-cause mortality, cardiovascular events, and hospitalization (4). Estimated glomerular filtration rate (eGFR) is strongly associated with the increased risk of all-cause mortality, cardiovascular events, and hospitalization. The prevalence of all stages of CKD in Taiwan is 12% (95% CI 11.7–12.3), and only 3.5% of patients are aware of their CKD (5). Patients with CKD stage 5 on dialysis had a higher risk of TB than the general population, and these patients are more likely to develop extra-pulmonary TB, especially TB peritonitis and lymphadenitis (6). The incidence of TB was 4.39 per 1000 person-year in CKD patients (7). Refugees with CKD in the Unite State had a higher rate of TB disease (1.9 vs. 0.8% of the general population) (8). None of the previous studies explore the association of renal function and risk of TB infection. We explored the association of eGFR and TB in non-dialysis CKD patients in this cohort study. Competing risks analysis was used because eGFR is associate with increase all-cause mortality.

METHODS

This is a prospective single-center observation study. All patients in the outpatient-based CKD program of China Medical University Hospital (CMUH) from June 2003 to May 2014 were enrolled in this study as per clinicians’ discretion. The CKD program included patients with CKD stages 1–5 without dialysis. The nephrologists made the diagnosis of CKD. The CKD program supported by National Health Insurance Taiwan includes clinical endocrinologists, nephrologists, CKD nurses, dietitians, and social workers. The purpose of the CKD program is to monitor the progress of CKD patients. As part of this program, laboratory measurements and CKD education are performed at least four times a year. Basic information, including age, gender, smoking history, and body mass index (BMI), was collected at enrollment. The basal eGFR estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (9) was used in the analysis. CKD was defined as an eGFR <60 ml/min/1.73 m² or markers for kidney damage for three months, and the eGFR and albuminuria defined the CKD stages (10). Hemoglobin, platelet, blood urea nitrogen (BUN), uric acid, fasting blood glucose (FBG), sodium, potassium, calcium, phosphate, albumin, cholesterol, and triglyceride were obtained within three months. All patients were followed from the date of enrollment to the detection of first TB infection, renal replacement therapy (RRT) including hemodialysis, peritoneal dialysis, kidney transplant, loss to follow-up, death, or December 2014. Internal review board approval (DMR 99-IRB-301) was obtained, and the need for informed consent was waived.

A definitive diagnosis of tuberculosis was positive culture for the Mycobacterium tuberculosis complex (N = 81), and a presumptive diagnosis of tuberculosis was defined as (1) positive sputum smear examination (positive for acid-fast stain), N = 0; (2) radiographic abnormality consistent with pulmonary TB and no response to current broad spectrum antibiotics that clinician decided to treat with a full course anti-tuberculosis chemotherapy, N = 14; (3) lymphocyte rich exudative pleural effusion adenosine deaminase (ADA) level more than 40 U/L (11), N = 5; and (4) histological finding consistent with TB infection (N = 14). The pulmonary TB case was a patient with a TB infection involving lung parenchyma. An extra-pulmonary case was a patient with TB infection with involvement of organs other than the lung. Patients who developed both pulmonary and extra-pulmonary tuberculosis were defined as having concomitant TB infection. This TB infection can refer to active TB infection because all patients received standard anti-tuberculosis therapy after the diagnosis.

Patients’ comorbidities were recorded at enrollment. Various comorbidities were as follows: Cardiovascular disease, which was defined as a positive exercise test, angiographic findings of at least one stenosis of >50%, or positive findings on scintigraphy. Diabetes was defined as insulin use, a hypoglycemic agent, or a fasting plasma glucose level of 126 mg/dl or more (12). Hypertension was defined as taking antihypertensives or having a systolic BP reading >140 mmHg or a diastolic BP reading >90 mmHg (13). Liver cirrhosis, defined as abnormal image finding with specific clinical laboratory date and manifestation (14). In addition, any form of cancer reported by the patient or detected from medical records was also recorded at enrollment.

Statistical Analysis

Data were reported as mean ± standard deviation, median (interquartile range), or frequency (percentage) as appropriate. We tested the distribution of continuous variables with skewness and kurtosis tests. Student’s t-test was applied for parametric variables, Kolmogorov-Smirnov test for non-parametric variables, and chi-square test for categorical variables. A subdistribution hazard ratio (SHR) and 95% confidence interval (95% CI) of the SHR of possible confounders were calculated using univariate competing-risks regression analysis followed by multivariate competing-risks regression (15). TB infection was defined as the primary event in the competing-risks regression, and the competing events include death or loss to follow-up. All analyses were performed using Stata software, version 12 SE (Stata Corp., College Station, TX). P-value of < 0.05 was considered to represent statistically significant differences.
TABLE 1 | Clinical characteristics of patients with and without tuberculosis (TB).

| Characteristics                  | Total N = 7221 | TB (–) N = 7107 | TB (+) N = 114 | p     |
|----------------------------------|---------------|-----------------|----------------|-------|
| Age (year)                       | 69 ±14        | 69 ±14          | 74 ±11         | <0.01 |
| Male gender n (%)                | 4153 (57.5)   | 4080 (57.4)     | 73 (64)        | 0.16  |
| BMI (kg/m²)                      | 24.4 ±4.1     | 24.5 ±2.8       | 23.8 ±2.8      | <0.01 |
| eGFR (ml/min/1.73m²)             | 35 ±26        | 35 ±26          | 25 ±18         | <0.01 |
| Smoking n (%)                    | 1189 (16.5)   | 1173 (16.5)     | 16 (14)        | 0.48  |
| Stage n (%)                      |               |                 |                |       |
| 1                                | 280 (3.9)     | 280 (4)         | 0              | 0.02  |
| 2                                | 664 (9.2)     | 661 (9.3)       | 3              | 0.26  |
| 3                                | 2704 (37.5)   | 2668 (37.5)     | 36             | 0.27  |
| 4                                | 1585 (22)     | 1555 (21.9)     | 30             | 0.29  |
| 5                                | 1988 (27.5)   | 1943 (27.3)     | 45             | 0.95  |
| Causes of kidney disease n (%)   |               |                 |                |       |
| Diabetes                         | 2769 (38.4)   | 2719 (38.3)     | 50             | 0.15  |
| Chronic glomerulonephritis       | 2381 (33.0)   | 2341 (32.9)     | 40             | 0.6   |
| Hypertension                     | 1173 (16.2)   | 1161 (16.3)     | 12             | 0.07  |
| Comorbidity n (%)                |               |                 |                |       |
| Cardiovascular disease           | 494 (6.8)     | 481 (6.8)       | 13             | 0.06  |
| Diabetes                         | 3094 (42.9)   | 3041 (42.8)     | 53             | 0.43  |
| Cancer                           | 354 (4.9)     | 350 (4.9)       | 4              | 0.35  |
| Liver cirrhosis                  | 222 (3.1)     | 215 (3)         | 7              | 0.06  |
| Hemoglobin (g/dl)                | 9.6 ±2.3      | 9.6 ±2.3        | 10             | 0.66  |
| Platelet (1000/µl)               | 196.9 ±74.8   | 196 ±75         | 193 ±83        | 0.65  |
| BUN (mg/dl)                      | 44 ±31        | 44 ±31          | 51 ±26         | 0.03  |
| Creatinine (mg/dl)               | 3.1 ±2.9      | 3.1 ±2.9        | 3.5 ±2.3       | 0.09  |
| Uric acid (mg/dl)                | 7.5 ±1.9      | 7 ±2            | 8              | 0.37  |
| Sodium (meq/L)                   | 138 ±3        | 137.9 ±3.4      | 138.6 ±3.4     | 0.38  |
| Potassium (meq/L)                | 4.4 ±0.7      | 4.4 ±0.7        | 4.4 ±0.5       | 0.07  |
| Calcium (mg/dl)                  | 8.8 ±0.6      | 8.8 ±0.6        | 8.5 ±0.7       | 0.09  |
| Phosphorus (mg/dl)               | 4.2 ±1.1      | 4.2 ±1.1        | 4.2 ±1.0       | 0.93  |
| Albumin (g/dl)                   | 3.8 ±2.9      | 3.8 ±2.9        | 3.6 ±0.6       | 0.65  |
| Cholesterol (mg/dl)              | 189 ±56       | 189 ±56         | 185 ±60        | 0.76  |
| Triglyceride (mg/dl)             | 165 ±183      | 165 ±184        | 135 ±78        | 0.52  |
| Fasting blood glucose (mg/dl)    | 136 ±56       | 137 ±56         | 130 ±51        | 0.65  |

BMI, body mass index; eGFR, estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation; BUN, blood urea nitrogen.

TABLE 2 | Clinical characteristics of tuberculosis patients.

| Tuberculosis infection site       | N = 114 (%) |
|----------------------------------|-------------|
| Pulmonary infection              | 57 (50.0)   |
| Concomitant infection            | 25 (21.9)   |
| Extra-pulmonary infection        | 32 (28.1)   |

Diagnosed method

| Sputum culture                   | 67 (58.8)   |
| Lung biopsy                      | 5 (4.4)     |
| Extra-pulmonary site culture     | 14 (12.3)   |
| Extrapulmonary site biopsy       | 9 (7.9)     |
| Pleural effusion ADA > 40 U/L    | 5 (4.4)     |
| By clinical presentation or image confirmed by expert | 14 (12.3) |

ADA, Adenosine deaminase.

RESULTS

In this study, 7,221 non-dialysis CKD stage 1–5 patients were included in the analysis (Table 1) and were followed up for a median period of 1.4 years (interquartile range: 0.7–2.4). Of these, 114 (1.6%) patients had TB infection, and 610 (14.6%) patients were lost to follow-up. The mortality rate was 4.1 per 100 patient-years, and the rate of patients requiring renal replacement therapy (RRT; including hemodialysis, peritoneal dialysis, and kidney transplant) was 12.1 per 100 patient-years. At enrollment, patients' basal eGFR was 35 ± 26 ml/min/1.73 m² and the distribution of patients among various CKD stages were as follows: stage 1, 3.9%; stage 2, 9.2%; stage 3, 37.5%; stage 4, 22%; and stage 5 27.5%. The most common cause of kidney disease was diabetes (38.4%), followed by chronic glomerulonephritis (33%) and hypertension (16.2%).
Of 114 patients with TB infection, 50% patients had pulmonary TB, 28.1% patients had extra-pulmonary TB, and 21.9% patients had concomitant pulmonary and extra-pulmonary TB infection (Table 2). TB infections were found in one location in 74.6% of patients, and 25.4% of patients had TB in more than one site. The most common extra-pulmonary TB infection sites in CKD patients were pleural (21.1%) and peritoneal infections (13.2%). Most TB infections were confirmed by the sputum culture (58.8%) followed by extra-pulmonary sites culture (12.3%), extra-pulmonary sites biopsy (7.9%), lung biopsy (7.0%), and pleural effusion ADA concentration more than 40 U/L (4.4%). Only 12.3% of TB cases at enrollment were diagnosed by the clinical presentation or image by the experts.

Patients with TB had lower eGFR (25 ± 18 ml/min/1.73 m²) compared to patients without TB (36 ± 26 ml/min/1.73 m²) (Table 1) and they had higher BUN (51 ± 26 mg/dl) than patients without TB (44 ± 31 mg/dl, p = 0.03). Patients who developed TB were older than those without TB (p < 0.01) and had a lower BMI (p < 0.001) than patients who did not have TB. The percentage of CKD stage 1 was higher in patients without TB, while the percentage of CKD stage 5 was higher in patients with TB (Figure 1). The causes of kidney disease were not different among patients with or without TB.

In univariable competing-risk analysis (Table 3), higher eGFR was associated with a lower risk of TB infection with a SHR of 0.84 (95% CI: 0.79–0.90, p < 0.01) per 5 ml/min/1.73 m². Among other factors, diabetes (p = 0.05), higher BUN (p < 0.01), higher creatinine (p < 0.01) were associated with the higher risk of TB infection while higher BMI (p = 0.04) and higher serum calcium (p = 0.02) were associated with lower risk of TB infection. Although patients’ age, gender, smoking, liver cirrhosis, and serum albumin were not significantly different for the development of TB infection in univariable analysis, these

### TABLE 3 | Subdistribution hazard ratios (SHRs) of possible confounders for tuberculosis in univariate competing-risks analysis.

| Possible confounders                      | SHR  | 95% CI          | p    |
|------------------------------------------|------|-----------------|------|
| eGFR (per 5 ml/min/1.73m² higher)        | 0.84 | 0.79–0.90       | <0.01|
| Age (per 10 additional years)            | 1.13 | 0.99–1.28       | 0.06 |
| Male                                     | 1.05 | 0.70–1.58       | 0.81 |
| Smoke                                    | 1.02 | 0.58–1.81       | 0.94 |
| BMI (every 1 kg²/m² higher)              | 0.94 | 0.88–0.99       | 0.04 |
| Diabetes                                 | 1.48 | 1.00–2.01       | 0.05 |
| Liver cirrhosis                          | 2.22 | 0.97–5.07       | 0.06 |
| Cardiovascular disease                   | 1.58 | 0.77–3.25       | 0.21 |
| Cancer                                   | 0.85 | 0.31–2.32       | 0.76 |
| Hemoglobin (every 1 g/dl higher)         | 0.91 | 0.62–1.33       | 0.63 |
| BUN (every 1 mg/dl higher)               | 1.02 | 1.01–1.02       | <0.01|
| Creatinine (every 1 mg/dl higher)        | 1.20 | 1.15–1.25       | <0.01|
| Uric acid (every 1 mg/dl higher)         | 1.21 | 0.89–1.64       | 0.22 |
| Sodium (every 1 meq/L higher)            | 1.07 | 0.91–1.26       | 0.42 |
| Potassium (every 1 meq/L higher)         | 1.45 | 0.80–2.62       | 0.22 |
| Calcium (every 1 mg/dl higher)           | 0.58 | 0.37–0.91       | 0.02 |
| Phosphorus (every 1 mg/dl higher)        | 1.16 | 0.74–1.82       | 0.52 |
| Albumin (every 1 g/dl higher)            | 0.86 | 0.55–1.36       | 0.53 |
| Cholesterol (every 1 mg/dl higher)       | 0.99 | 0.99–1.01       | 0.79 |
| Triglyceride (every 1 mg/dl higher)      | 1.00 | 0.99–1.00       | 0.32 |
| FBG (every 1 mg/dl higher)               | 1.00 | 0.99–1.01       | 0.97 |

eGFR, estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation; BMI, body mass index; BUN, blood urea nitrogen; FBG, fasting blood glucose.

Diabetes was also the most common comorbidity in CKD patients. Basal laboratory parameters' values were recorded in Table 1.
Smoking is one of the most common host-related factors associated with TB infection (30–32). However, we did not find a significant association between smoking and TB infection in our patients. The low prevalence of smoking may explain this. Malnutrition is another important host-related factor associated with TB infection (33–35). We found that CKD patients with lower BMI were associated with increased TB infection risk in multivariable analysis, but it did not mean malnutrition because the mean and standard deviation were within normal limits. The serum albumin level at enrollment was not significantly associated with TB infection in this study. The association between BMI and TB infection may be explained by chronic inflammation. Chronic inflammation is one of the non-traditional cardiovascular disease risks. Interleukin-6 is a marker for chronic inflammation and is negatively correlated to BMI (36). Further studies are needed to explore the interaction of interleukin-6, BMI, and TB infection.

50% of patients had pulmonary TB, and the other 50% had extra-pulmonary TB or concomitant TB infection. The percentage of extra-pulmonary infection plus concomitant infection was similar to the previous report (37) (48.4% of pulmonary TB; 37.7% of extra-pulmonary TB, and 13.9% concomitant infection in maintenance dialysis patients). This distribution is different from that of the general population (82.3% of pulmonary TB, 10.6% of extra-pulmonary TB, and 7.1% concomitant infection) (37). One of the unique characteristics of TB infection in dialysis patients is the high rate of extra-pulmonary infection, especially lymphadenitis (6, 37). In our report, the most common infections were pleural and peritoneal infections.

There were some potential limitations in this study. Information about steroid or biologics use was not recorded, and hence an association of steroid or biologics and TB infection could not be analyzed. It was a potential source bias. Some confoundings of TB infection were not recorded, such as alcohol consumption, drug dependence, migrants, unemployed, and homeless individuals. None of our patients had HIV infection.

**DISCUSSION**

Higher renal function was associated with a lower risk of TB infection with adjustments for confounders for TB infection in the multivariate competing-risks analysis (Table 4) and the cumulative TB risk according to CKD stage (Figure 2). The competing-risks regression analysis was used because eGFR was also associated with all-cause mortality, and the risk of TB infection may be explained by chronic inflammation. Chronic inflammation is one of the non-traditional cardiovascular disease risks. Interleukin-6 is a marker for chronic inflammation and is negatively correlated to BMI (36). Further studies are needed to explore the interaction of interleukin-6, BMI, and TB infection.

| Possible confounders | aSHR | 95% CI | p     |
|---------------------|------|--------|-------|
| eGFR (per 5 ml/min/1.73 m² higher) | 0.82 | 0.72–0.94 | <0.01 |
| Age (per 10 additional years) | 0.98 | 0.79–1.23 | 0.89 |
| Male | 1.44 | 0.76–2.73 | 0.26 |
| BMI (every 1 kg/m² higher) | 0.91 | 0.85–0.98 | 0.01 |
| Smoking | 0.84 | 0.35–2.01 | 0.70 |
| Diabetes | 1.53 | 0.84–2.80 | 0.17 |
| Liver cirrhosis | 2.72 | 0.96–7.70 | 0.06 |
| Calcium (every 1 mg/dl higher) | 0.59 | 0.29–1.20 | 0.15 |
| Albumin (every 1 g/dl higher) | 0.99 | 0.97–1.02 | 0.59 |

*Table 4* | Adjusted subdistribution hazard ratios (aSHRs) of possible confounders for tuberculosis in multivariate competing-risks analysis.

**FIGURE 2** | Cumulative incidence of tuberculosis in competing-risks analysis of patients with chronic kidney disease with adjustments for patients’ age, gender, body mass index, diabetes, liver cirrhosis, serum calcium, and serum albumin.

Factors important risk factors of TB infection and were included in multivariable analysis (Table 4). Higher eGFR was independently associated a lower risk of TB infection with an adjusted SHR (aSHR) of 0.82 (95% CI: 0.72–0.94, p < 0.01). Higher BMI was also independently associated with a lower risk of TB infection (p = 0.01). The cumulative incidence of TB infection as per patients’ CKD stages is shown in Figure 2. The risk of TB infection was highest in patients with CKD stage 5, followed by patients with CKD stage 4, stage 3, stage 2, and the risk were lowest in patients with CKD stage 1 (p < 0.01) with adjustment for patients’ age, gender, BMI, diabetes, liver cirrhosis, calcium, and albumin.

**FIGURE 2** | Cumulative incidence of tuberculosis in competing-risks analysis of patients with chronic kidney disease with adjustments for patients’ age, gender, body mass index, diabetes, liver cirrhosis, serum calcium, and serum albumin.
We are not able to analyze the association between TB infection and HIV. The generalizability of our findings is limited by the outpatient settings and CKD cohort of one hospital. Further studies of multiple institutions in different ethnic groups are needed to validate our findings.

CONCLUSIONS

The risk of tuberculosis is negatively correlated with the renal function determined by using the estimated glomerular filtration rate, and this association is independent of patients’ body mass index, age, and comorbidity in non-dialysis CKD patients. Physicians should pay more attention to the risk of tuberculosis infection in clinical practice, especially in patients with advanced kidney disease.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Internal review board approval (DMR 99-IRB-301). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

C-HL, H-JC, D-TB, and C-YC were responsible for protocol design, data analysis, discussion, manuscript writing, and proofreading. W-CC, C-YT, T-CH, W-HH, C-TC, and C-CH were responsible for data collection. C-HL, D-TB, and C-YT were responsible for all work supervision and final manuscript approval. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV-negative patients: a systematic review. PLoS ONE. (2011) 6:e17601. doi: 10.1371/journal.pone.0017601
2. Global tuberculosis report 2018. Geneva: World Health, Organization, 2018. Licence: CC BY-NC-SA 3.0 IGO (2018).
3. M.o.H.a.W. Centers for Disease Control, R.O.C. (Taiwan). Taiwan Tuberculosis Control Report 2013. Centers for Disease Control, Ministry of Health and Welfare, R.O.C. (2014).
4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. (2004) 351:1296–305. doi: 10.1056/NEJMoa041031
5. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet. (2008) 371:2173–82. doi: 10.1016/S0140-6736(08)60952-6
6. Hussein MM, Mooji JM, Roujouleh H. Tuberculosis and chronic renal disease. Semin Dial. (2003) 16:36–44. doi: 10.1046/j.1525-139X.2003.03010.x
7. Cheng KC, Liao KF, Lin CL, Liu CS, Lai SW. Chronic kidney disease correlates with increased risk of pulmonary tuberculosis before initiating renal replacement therapy: a cohort study in Taiwan. Medicine. (2018) 97:e12550. doi: 10.1097/MD.0000000000012550
8. Bardenheier BH, Pavkov ME, Winston CA, Klosovsky A, Yen C, Benoit S, et al. Prevalence of tuberculosis disease among adult us-bound refugees with chronic kidney disease. J Immigr Minor Health. (2019) 21:1275–81. doi: 10.1007/s10903-018-0852z-8
9. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro III AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. (2009) 150:664–12. doi: 10.7326/0003-4819-150-9-20090505-00006
10. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. (2014) 63:713–35. doi: 10.1053/j.ajkd.2014.01.416
11. Vorster MJ, Allwood BW, Diacon AH, Koegelenberg CF. Tuberculous pleural effusions: advances and controversies. J Thorac Dis. (2015) 7:981–91. doi: 10.3978/j.issn.2072-1439.2015.02.18
12. Gottlieb DJ, Punjabi NM, Newman AB, Resnick HE, Redline S, Baldwin CM, et al. Association of sleep time with diabetes mellitus and impaired glucose tolerance. Arch Intern Med. (2005) 165:863–7. doi: 10.1001/archinte.165.8.863
13. Lavie P, Herer P, Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. BMJ. (2000) 320:479–82. doi: 10.1136/bmj.320.7233.479
14. Runyon BA, A. primer on detecting cirrhosis and caring for these patients without causing harm. Int J Hepatol. (2011) 2011:801983. doi: 10.4061/2011/801983
15. Fine JP, Gray RJ, A. proportional hazards model for the subdivision of a competing risk. J Am Stat Assoc. (1999) 94:496–509. doi: 10.1080/01621459.1999.10474144
16. Noordzij M, Leffondré K, van Stralen KJ, Zoccali C, Dekker FW, Jager KJ. When do we need competing risks methods for survival analysis in nephrology? Nephrol Dial Transplant. (2013) 28:2670–7. doi: 10.1093/ndt/gft335
17. Baker MA, Lin HH, Chang HY, Murray MB. The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study. Clin Infect Dis. (2012) 54:818–25. doi: 10.1093/cid/cir939
18. Shen TC, Lin CL, Wei CC, Liao WC, Chen WC, Chen CH, et al. Increased risk of tuberculosis in patients with type 1 diabetes mellitus: results from a population-based cohort study in Taiwan. Medicine. (2014). 93:e96. doi: 10.1097/MD.0000000000000096
19. Lin YT, Wu PH, Lin CY, Lin MY, Chuang HY, Huang JE, et al. Cirrhosis as a risk factor for tuberculosis infection–a nationwide longitudinal study in Taiwan. Am J Epidemiol. (2014) 180:103–10. doi: 10.1093/aje/kwu095
20. Steiger Z, Nickel WO, Shannon GJ, Nedwicki EG, Higgins RF. Pulmonary tuberculosis after gastric resection. Am J Surg. (1976) 131:668–71. doi: 10.1016/0002-9617(76)91074-4
21. Ricardo SD, Van Goor H, Eddy AA. Macrophage diversity in renal injury and repair. J Clin Invest. (2008) 118:3522–30. doi: 10.1172/JCI36150
22. Levin A, Bakris GL, Moltch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin DPTH calcium, and phosphorus in people with chronic kidney disease. Kidney Int. (2008) 73:956–62. doi: 10.1038/ki.2008.200
23. Gutierrez OM, Isakova T, Andress DL, Levin A, Wolf M. Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease. Kidney Int. (2008) 73:956–62. doi: 10.1038/ki.2008.200
24. Penna G, Roncari A, Amuchastegui S, Daniel KC, Berti E, Colonnà M, et al. Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by l-2,5-dihydroxyvitamin D3. Blood. (2005) 106:3490–7. doi: 10.1182/blood-2005-05-2044
25. Brown AJ, Fusso AS, Slatopolsky E. Vitamin D American journal of physiology. Renal Physiol. (2005) 289:F8–28. doi: 10.1152/ajprenal.00336.2004
26. DeLuca HF. Overview of general physiologic features and functions of vitamin D. *American J Clin Nutr.* (2004) 80:1689S–96S. doi: 10.1093/ajcn/80.6.1689S

27. Gibney KB, MacGregor L, Leder K, Torresi J, Marshall C, Ebeling PR, et al. Vitamin D deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from sub-Saharan Africa. *Clin Infect Dis.* (2008) 46:443–6. doi: 10.1086/525268

28. Holick MF. Vitamin D deficiency. *N Engl J Med.* (2007) 357:266–81. doi: 10.1056/NEJMra070553

29. Bikle DD. Vitamin D and the immune system: role in protection against bacterial infection. *Curr Opin Nephrol Hypertens.* (2008) 17:348–52. doi: 10.1097/MNH.0b013e3282ff6a3

30. Leung CC, Yew WW, Chan CK, Chang KC, Law WS, Lee SN, et al. Smoking adversely affects treatment response, outcome and relapse in tuberculosis. *Eur Respir J.* (2015) 45:738–45. doi: 10.1183/09031936.00114214

31. Lönnroth K, Williams BG, Stadlin S, Jaramillo E, Dye C. Alcohol use as a risk factor for tuberculosis - a systematic review. *BMC Public Health.* (2008) 8:289. doi: 10.1186/1471-2458-8-289

32. Lin HH, Ezzati M, Chang HY, Murray M. Association between tobacco smoking and active tuberculosis in Taiwan: prospective cohort study. *Am J Respir Crit Care Med.* (2009) 180:475–80. doi: 10.1164/rccm.200904-0549OC

33. Cegielski JP, McMurray DN. The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals. *Int J Tuberc Lung Dis.* (2004) 8:286–98.

34. Leung CC, Lam TH, Chan WM, Yew WW, Ho KS, Leung G, et al. Lower risk of tuberculosis in obesity. *Arch Intern Med.* (2007) 167:1297–304. doi: 10.1001/archinte.167.12.1297

35. Tverdal A. Body mass index and incidence of tuberculosis. *Eur J Respir Dis.* (1986) 69:355–62.

36. Mahuad C, Bozza V, Pezzotto SM, Bay ML, Besedovsky H, del Rey A, et al. Impaired immune responses in tuberculosis patients are related to weight loss that coexists with an immunoendocrine imbalance. *Neuroimmunomodulation.* (2007) 14:193–9. doi: 10.1159/00010646

37. Chou KJ, Fang HC, Bai KJ, Hwang SJ, Yang WC, Chung HM. Tuberculosis in maintenance dialysis patients. *Nephron.* (2001) 88:138–43. doi: 10.1159/000045974

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Li, Chen, Chen, Tu, Hsia, Hsu, Chang, Huang, Bau and Chou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.